Literature DB >> 29795432

CAR T cells induce a complete response in refractory Burkitt Lymphoma.

Abraham Avigdor1, Roni Shouval2, Elad Jacoby2, Tima Davidson2, Avichai Shimoni2, Michal Besser2, Arnon Nagler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29795432     DOI： 10.1038/s41409-018-0235-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

Review 1.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 2.  Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.

Authors:  Adam S Zayac; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2020-04-07

Review 3.  Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Authors:  Emily M Hsieh; Rayne H Rouce
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.

Authors:  Samantha J Seitter; Paul H McClelland; Mark A Ahlman; Stephanie L Goff; James C Yang; Lori McIntyre; Steven A Rosenberg; James N Kochenderfer; Jennifer N Brudno
Journal:  Leuk Lymphoma       Date:  2022-06-09

5.  Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Authors:  Jiaying Wu; Yang Cao; Qi Zhang; Wanying Liu; Xiaoxi Zhou; Xi Ming; Fankai Meng; Yicheng Zhang; Chunrui Li; Liang Huang; Jia Wei; Miao Zheng; Shangkun Zhang; Tongcun Zhang; Xiaojian Zhu; Na Wang; Jue Wang; Gaoxiang Wang; Jianfeng Zhou; Bo Liu; Yi Xiao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

6.  Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma.

Authors:  Meirav Kedmi; Roni Shouval; Shalev Fried; David Bomze; Joshua Fein; Zachary Cohen; Ivetta Danilesko; Noga Shem-Tov; Ronit Yerushalmi; Elad Jacoby; Michal Besser; Avichai Shimoni; Arnon Nagler; Abraham Avigdor
Journal:  Transplant Cell Ther       Date:  2022-02-23

7.  Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Tianyi Wang; Mingxuan Feng; Chengjuan Luo; Xinyu Wan; Ci Pan; Jingyan Tang; Feng Xue; Minzhi Yin; Dongqing Lu; Qiang Xia; Benshang Li; Jing Chen
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

8.  Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies.

Authors:  Huiqing Xiu; Xi Nan; Danfeng Guo; Jiaoli Wang; Jiahui Li; Yanmei Peng; Guirun Xiong; Shibo Wang; Changjun Wang; Gensheng Zhang; Yunshan Yang; Zhijian Cai
Journal:  Asian J Pharm Sci       Date:  2022-04-30       Impact factor: 9.273

Review 9.  Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.

Authors:  Coen J Lap; Samah Nassereddine; Kieron Dunleavy
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

10.  Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.

Authors:  Orit Itzhaki; Elad Jacoby; Abraham Nissani; Michal Levi; Arnon Nagler; Adva Kubi; Karin Brezinger; Hadar Brayer; Li-At Zeltzer; Meir Rozenbaum; Helly Vernitsky; Gal Markel; Amos Toren; Abraham Avigdor; Jacob Schachter; Michal J Besser
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.